2′,2′-Difluoro-2′-deoxycytidine-3′,5′-dibenzoate

We are 2′,2′-Difluoro-2′-deoxycytidine-3′,5′-dibenzoate CAS:134790-39-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:2',2'-Difluoro-2'-deoxycytidine-3',5'-dibenzoate
CAS.NO:134790-39-9
Synonyms:GeMcitabine InterMediate 9
3',5'-Di-O-benzoyl-2'-deoxy-2',2'-difluorocytidine
2'-deoxy-2,2'-difluoro-3,5-dibenzyl-cytidine; Chloropurine riboside
Molecular Formula:C23H19F2N3O6
Molecular Weight:471.41000
 
Physical and Chemical Properties:
Density:1.459
Melting point:229-232ºC
Boiling point:608.383ºC
Flash point:321.739ºC
Index of Refraction:1.625
 
Specification:
Appearance:Off-white solid
Purity:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Gemcitabine intermediate

2',2'-Difluoro-2'-deoxycytidine-3',5'-dibenzoate


Related News: Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.77-55-4 Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.4-bromobutan-1-ol From the perspective of the overall life cycle of generic drugs from R & D to sales, with the expiration of patents, the business model for the production and marketing of generic pharmaceutical raw materials has changed, demand has increased, business potential has been realized quickly, and gross profit margins have shown a downward trend.2,3-Difluoro-6-methylpyridine CAS:1227579-04-5 This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?

Related Products
Product Name
2-Methylresorcinol View Details
N,O-Bis(trimethylsilyl)acetamide View Details
2-Hydroxy-5-trifluoromethylpyridine View Details
Propylphosphonic Acid Anhydride manufacturer 9-(4,6-diphenyl-1,3,5-triazin-2-yl)-9′-phenyl-3,3′-bicarbazole manufacturer 4-piperidin-3-ylaniline manufacturer 4-[(5-bromo-4,6-dichloropyrimidin-2-yl)amino]benzonitrile manufacturer 2,4-Dibromomesitylene manufacturer